We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Releases Positive U.S. & U.K. Study Data on COPD
Read MoreHide Full Article
ResMed Inc. (RMD - Free Report) recently demonstrated a favorable outcome from two clinical analyses in the field of chronic obstructive pulmonary disease (COPD). These studies were conducted for the United Kingdom and the United States, highlighting the cost effectiveness of combining home oxygen therapy with home non-invasive ventilation (NIV) therapy for persistent hypercapnia patients, who suffer exacerbation of COPD.
The combo regimen of Home Oxygen Therapy-Home Mechanical Ventilation (a home NIV), together known as HOT-HMV, has been presented at the American Thoracic Society 2018 International Conference. These are company-sponsored health economic studies.
Going by the U.K. study, HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmission. Data from the analysis was used to develop an economic model from the U.K. National Health Service perspective. While the U.S. study demonstrated a 58.3% reduction in 30-day readmissions for HOT-HMV patients compared with those on home oxygen alone. Evidently, this indicated the treatment to be hugely cost effective. Per ResMed, the U.S. analysis was based on the U.K. study. The study finds were utilized to build an economic model from the U.S. payer perspective.
We are optimistic about this entire development by ResMed, taking into consideration the widely growing market for COPD treatment. Per data provided by GBI Research, the global COPD market is currently worth $11.3 billion and is projected to reach a value of $15.6 billion by 2019. According to the research report, this gaping demand will be met through numerous new, efficient and convenient products making inroads into the market.
Undoubtedly, ResMed’s HOT-HMV studies and the related favorable outcomes are a step forward for the company to intensify its footprint in the niche market.
Notably, ResMed achieved strong global revenue growth over the past few quarters, led by sales of sleep devices, respiratory care devices, mask systems as well as software solutions. We believe, ResMed’s product launches and strategies will gain traction in the SDB market and are expected to drive growth for the company in the near term.
Among recent developments, the company informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP (positive airway pressure) device.
In the past three months, ResMed has outperformed its industry. The stock has gained 9% compared with the 5.1% rise of the industry.
Zacks Rank & Key Picks
ResMed currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Intuitive Surgical (ISRG - Free Report) , Illumina, Inc (ILMN - Free Report) and The Cooper Companies, Inc. (COO - Free Report) . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Cooper Companies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Illumina has a long-term expected earnings growth rate of 20%.
The Cooper Companies has a long-term expected earnings growth rate of 10.8%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ResMed Releases Positive U.S. & U.K. Study Data on COPD
ResMed Inc. (RMD - Free Report) recently demonstrated a favorable outcome from two clinical analyses in the field of chronic obstructive pulmonary disease (COPD). These studies were conducted for the United Kingdom and the United States, highlighting the cost effectiveness of combining home oxygen therapy with home non-invasive ventilation (NIV) therapy for persistent hypercapnia patients, who suffer exacerbation of COPD.
The combo regimen of Home Oxygen Therapy-Home Mechanical Ventilation (a home NIV), together known as HOT-HMV, has been presented at the American Thoracic Society 2018 International Conference. These are company-sponsored health economic studies.
Going by the U.K. study, HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmission. Data from the analysis was used to develop an economic model from the U.K. National Health Service perspective. While the U.S. study demonstrated a 58.3% reduction in 30-day readmissions for HOT-HMV patients compared with those on home oxygen alone. Evidently, this indicated the treatment to be hugely cost effective. Per ResMed, the U.S. analysis was based on the U.K. study. The study finds were utilized to build an economic model from the U.S. payer perspective.
We are optimistic about this entire development by ResMed, taking into consideration the widely growing market for COPD treatment. Per data provided by GBI Research, the global COPD market is currently worth $11.3 billion and is projected to reach a value of $15.6 billion by 2019. According to the research report, this gaping demand will be met through numerous new, efficient and convenient products making inroads into the market.
Undoubtedly, ResMed’s HOT-HMV studies and the related favorable outcomes are a step forward for the company to intensify its footprint in the niche market.
Notably, ResMed achieved strong global revenue growth over the past few quarters, led by sales of sleep devices, respiratory care devices, mask systems as well as software solutions. We believe, ResMed’s product launches and strategies will gain traction in the SDB market and are expected to drive growth for the company in the near term.
Among recent developments, the company informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP (positive airway pressure) device.
In the past three months, ResMed has outperformed its industry. The stock has gained 9% compared with the 5.1% rise of the industry.
Zacks Rank & Key Picks
ResMed currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are Intuitive Surgical (ISRG - Free Report) , Illumina, Inc (ILMN - Free Report) and The Cooper Companies, Inc. (COO - Free Report) . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Cooper Companies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Illumina has a long-term expected earnings growth rate of 20%.
The Cooper Companies has a long-term expected earnings growth rate of 10.8%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>